top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Aug 12, 2024
Clinical Research Law: A Historic Regulatory Milestone for Clinical Trial with Human Beings in Brazil
Feb 7, 2024
Find out about Anvisa's priorities for the next biennium
Nov 21, 2023
RDC 753 - New Regulatory Framework for the Registration of Synthetic Drugs.
Oct 26, 2023
WHAT ARE THE STEPS FOR OBTAINING AUTHORIZATION FOR CLINICAL STUDIES IN BRAZIL?
Oct 9, 2023
Important circumstances for the submission of drug registration in Brazil
Aug 22, 2023
What is the purpose of registration submission guide, based on data from scientific literature?
Jul 24, 2023
Biological and biosimilar medicines - development and commercialization challenges
Apr 8, 2022
Pharmaceutical Industry – focused on the future
Apr 7, 2022
ANVISA – Post-pandemic challenges and perspectives.
Apr 7, 2022
Clinical research in Brazil - regulation is important and urgent!
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
